How Oxandrolone Affects DHT

Oxandrolone is a 2-oxa-17-alpha-methyl derivative of dihydrotestosterone. It is already in the DHT family structurally, which has two important pharmacological consequences:

1. Direct AR activation in DHT-sensitive tissues: Oxandrolone binds androgen receptors in scalp follicles, vocal fold tissue, sebaceous glands, and clitoral tissue with high affinity. It does not require conversion by 5-alpha-reductase to produce DHT-like effects.
2. Finasteride and dutasteride do nothing: These drugs block the conversion of testosterone to DHT by inhibiting 5-alpha-reductase. Oxandrolone is already a DHT-derivative AR agonist, so blocking the upstream conversion pathway is irrelevant. Women asking about finasteride for anavar-related hair loss are asking the wrong question.

Serum DHT levels can rise modestly on oxandrolone (the compound itself cross-reacts with some DHT assays and increases endogenous DHT production via SHBG suppression). But the tissue-level androgenic burden is much higher than serum DHT alone suggests, because oxandrolone is itself activating the same receptors DHT does.

Replacement-context low doses (5 mg/day):

• Serum DHT rises 1.5 to 2.5 fold above baseline
• Female baseline 0.1 to 0.7 nmol/L typically climbs to 0.5 to 1.0 nmol/L
• Tissue-level androgenic activity is higher than serum suggests

Standard bodybuilding doses in women (10 to 20 mg/day):

• Serum DHT often exceeds the female reference range (0.7 nmol/L)
• Receptor saturation in scalp, skin, and vocal tissue at 4 to 6 weeks
• First visible signs (acne, body hair, scalp thinning) begin appearing weeks 6 to 12

Timing of physical changes:

• Acne and oily skin: weeks 2 to 4 (fastest tissue response)
• Body and facial hair: weeks 6 to 12
• Scalp hair thinning at temples: weeks 8 to 16
• Voice changes: weeks 6 to 12+, often subtle initially
• Clitoral changes: variable, weeks 4 to 16

The blood markers (SHBG, free T, DHT) move 2 to 4 weeks before physical changes, giving a monitoring window to stop before irreversible damage.

Baseline before starting: Pull DHT along with SHBG, total testosterone, free testosterone, LH, FSH, estradiol. Female DHT reference is typically under 0.7 nmol/L (under 200 pg/mL).

Week 4 to 6 (mid-cycle): Repeat DHT + SHBG + free T. DHT rising above 0.7 nmol/L is the cue to stop.

Action thresholds:

• DHT above 0.7 nmol/L (female reference upper limit): stop. Tissue receptor saturation is real and irreversible changes accelerate.
• Any subjective voice change, persistent scalp itch at temples, or new clitoral sensitivity: stop regardless of DHT number. The serum number lags tissue effects.

Post-cycle: DHT normalizes within 2 to 4 weeks of stopping oxandrolone (short compound half-life ~9 to 10 hours). The serum marker drops fast; tissue-level changes from cumulative exposure do not.

Reducing DHT-driven damage:

• Lower the dose: 10 mg/day produces meaningfully less tissue AR saturation than 20 mg/day
• Shorter cycles: 4 to 6 weeks limits cumulative exposure
• Topical minoxidil 5 percent twice daily can slow scalp hair loss but won't reverse follicular miniaturization
• Voice rest and hydration may slow vocal fold remodeling but cannot prevent it once thickening starts
• Spironolactone post-cycle (50 to 200 mg/day under physician supervision) can slow new body hair growth and reduce sebaceous activity

What doesn't work:

• Finasteride and dutasteride: oxandrolone is a DHT derivative, blocking 5-alpha-reductase is irrelevant
• Saw palmetto or other 5-alpha-reductase inhibitors: same reason
• Cyproterone has direct AR antagonism but is rarely available outside Europe and carries its own side effect profile

The cardinal rule: Stop at the first physical sign (acne, voice scratchiness, temple recession, persistent clitoral sensitivity). The blood markers gave you the early warning weeks earlier; the physical signs mean tissue changes are already happening.